University Health Network

SAGA Diagnostics announced the U.S. commercial launch of Pathlight, a first-of-its-kind multi-cancer molecular residual disease platform initially indicated for early breast cancer.

Avicanna Inc. has entered a Sponsored Research Agreement to fund a Phase II clinical study evaluating oral cannabis extracts for osteoarthritis pain, scheduled to begin in Fall 2025.

Adela's methylation-based circulating tumor DNA test demonstrated ability to predict progression-free survival and overall survival in patients receiving immunotherapy across multiple solid tumor types.

• Zenflow's Spring System demonstrated 46% improvement in IPSS scores at 36 months post-placement, with 74% of patients achieving clinically significant symptom relief for benign prostatic hyperplasia. • The minimally invasive device maintained consistent efficacy over three years without compromising sexual function, positioning it as a leader in the emerging First-Line Interventional Therapy (FIT) category. • Results presented at the 2025 AUA Meeting represent the longest-term data among FIT interventions, with the company now advancing toward FDA approval through its multi-center BREEZE study.

A phase III trial showed that adding a single fraction of palliative radiotherapy to best supportive care significantly reduced pain in patients with painful hepatic cancer.